Retinoic acid syndrome: Difference between revisions
No edit summary |
Ostermayer (talk | contribs) (Text replacement - " pts" to " patients") |
||
| Line 1: | Line 1: | ||
==Background== | ==Background== | ||
*Differentiation syndrome (DS) is most current term | *Differentiation syndrome (DS) is most current term | ||
*APML | *APML patients undergoing ATRA treatment (Tretinoin, Vesanoid) | ||
**And/or with arsenic trioxide therapy (Trisenox, ATO) | **And/or with arsenic trioxide therapy (Trisenox, ATO) | ||
**Chemo Tx differentiates APML blasts into mature granulocytes | **Chemo Tx differentiates APML blasts into mature granulocytes | ||
**Differentiation of blasts may cause "cytokine storm" leading to tissue damage | **Differentiation of blasts may cause "cytokine storm" leading to tissue damage | ||
*Incidence of DS<ref>Montesinos P and Sanz MA. The Differentiation Syndrome in Patients with Acute Promyelocytic Leukemia: Experience of the Pethema Group and Review of the Literature. Mediterr J Hematol Infect Dis. 2011; 3(1): e2011059.</ref> | *Incidence of DS<ref>Montesinos P and Sanz MA. The Differentiation Syndrome in Patients with Acute Promyelocytic Leukemia: Experience of the Pethema Group and Review of the Literature. Mediterr J Hematol Infect Dis. 2011; 3(1): e2011059.</ref> | ||
**Up to 25% of | **Up to 25% of patients undergoing ATRA | ||
**Up to 31% of | **Up to 31% of patients undergoing ATO | ||
*Up to 40% mortality in patients requiring mechanical ventilation | *Up to 40% mortality in patients requiring mechanical ventilation | ||
*Diagnosis made clinically with symptomology | *Diagnosis made clinically with symptomology | ||
Revision as of 16:49, 21 June 2016
Background
- Differentiation syndrome (DS) is most current term
- APML patients undergoing ATRA treatment (Tretinoin, Vesanoid)
- And/or with arsenic trioxide therapy (Trisenox, ATO)
- Chemo Tx differentiates APML blasts into mature granulocytes
- Differentiation of blasts may cause "cytokine storm" leading to tissue damage
- Incidence of DS[1]
- Up to 25% of patients undergoing ATRA
- Up to 31% of patients undergoing ATO
- Up to 40% mortality in patients requiring mechanical ventilation
- Diagnosis made clinically with symptomology
- Requires immediate treatment with steroids
- Steroids highly recommended even if other ddx possible
Clinical Features
- Unexplained fever
- Unexplained hypotension
- Weight gain > 5 kg
- Dyspnea with pulmonary infiltrates
- Pericardial effusion
- Pleural effusion
- Renal failure
- Vascular capillary leak syndrome
- DIC
- Never observed beyond induction therapy, when pt has achieved complete response
Differential Diagnosis
- Sepsis
- Fungal infection
- Pulmonary hemorrhage
- Pneumonia
- Renal failure
- CHF
- Pulmonary embolism
- DIC
Diagnosis
- Troponins for pericarditis
- Severe leukocytosis on CBC
- Sepsis workup
- CHF workup, echo
- Pulmonary embolism workup
- DIC workup
- Coagulation factor levels
- Diagnostic bronchoscopy, BAL, bx usually not required
- Imaging
- CXR - pleural effusions, ground-glass opacities, increased cardiac silhouette
- CT chest - pleural effusions, peripheral nodules
Management[2]
- Dexamethasone 10 mg IV q12hrs
- Most important therapy, with possible dramatic and rapid resolution of symptoms
- Continue treatment until complete disappearance of signs and symptoms
- Temporary d/c ATRA or ATO only in severe cases of DS (renal failure or ICU admit)
- Supportive
- Mechanical ventilation for respiratory failure
- Careful IVF admin, prioritizing blood products for coagulopathies (DIC)
- Furosemide for fluid overload
- CRRT/HD for refractory renal failure
- Vasopressors
- Empiric antibiotics
- Avoid invasive pleural/pericardial effusion diagnostics
Disposition
See Also
External Links
References
- ↑ Montesinos P and Sanz MA. The Differentiation Syndrome in Patients with Acute Promyelocytic Leukemia: Experience of the Pethema Group and Review of the Literature. Mediterr J Hematol Infect Dis. 2011; 3(1): e2011059.
- ↑ Sanz MA and Montesinos P. How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia. May 1, 2014; Blood: 123 (18).